<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05083299</url>
  </required_header>
  <id_info>
    <org_study_id>DWAP_P401</org_study_id>
    <nct_id>NCT05083299</nct_id>
  </id_info>
  <brief_title>Multicenter, Therapeutic Use Observational Study to Evaluate the Effects of Concurrent Therapy of Sarpogrelate</brief_title>
  <official_title>Multicenter, Therapeutic Use Observational Study to Evaluate the Effects of Concurrent Therapy of Sarpogrelate on Symptom Improvement in Patients With Peripheral Arterial Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the effect of Anpl-one SR Tablet on the improvement of symptoms in&#xD;
      daily care environments using PAQ.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the effect of Anple-one SR Tablet on the improvement&#xD;
      of symptoms in daily care environments within the scope of 300 milligrams of Anpl-one SR&#xD;
      Tablet (sarpogrelate hydrochloride agent) using PAQ.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>change in PAQ</measure>
    <time_frame>24 weeks</time_frame>
    <description>change in PAQ at 24 weeks from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in PAQ</measure>
    <time_frame>12 weeks and 24 weeks</time_frame>
    <description>change in PAQ at 12 weeks and 24 weeks from baseline</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1884</enrollment>
  <condition>Arteriosclerosis Obliterans</condition>
  <arm_group>
    <arm_group_label>Anpl-one SR Tablet</arm_group_label>
    <description>Patients who prescribed Anpl-one SR Tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sarpogrelate</intervention_name>
    <description>Anpl-one SR</description>
    <arm_group_label>Anpl-one SR Tablet</arm_group_label>
    <other_name>Anpl-one SR</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        As a result of the calculation for the number of survey subjects in this study, a total of&#xD;
        1507 subjects are required, and a total of 1,884 subjects are planned to be recruited in&#xD;
        consideration of the dropout rate of 20%.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults over 19 and under 80 years of age.&#xD;
&#xD;
          2. Patients who first administered Sarpogrelate hydrochloride drugs or less than 3 months&#xD;
             to improve ischemic symptoms such as ulcers, pain, and coldness caused by chronic&#xD;
             arterial obstruction (Burger's disease, obstructive arteriosclerosis, diabetic&#xD;
             peripheral angiopathy, etc.).&#xD;
&#xD;
          3. Patient who voluntarily signed a written consent form approved by the Clinical Trial&#xD;
             Review Committee or Ethics Committee and agreed to participate in the study by the&#xD;
             patient or the subject's agent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient who is expected to have less than two years of life expectancy.&#xD;
&#xD;
          2. Patient who have bleeding within a week of participation in the study&#xD;
&#xD;
          3. Patient suffering from diseases that may increase bleeding during study participation&#xD;
             (hemophilia, capillary placebo, digestive tube ulcer, urinary tract bleeding,&#xD;
             hemoptysis, hyperself-bleeding, etc.).&#xD;
&#xD;
          4. A female patient who is likely to be pregnant or pregnant.&#xD;
&#xD;
          5. Female patients who are lactating or are scheduled to be lactated at the time of&#xD;
             participation in the study.&#xD;
&#xD;
          6. Patients with severe renal disease and liver disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>BuKyung Kim</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kosin University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>HeeJin Kim</last_name>
    <phone>82-02-550-8335</phone>
    <email>hjkim221@daewoong.co.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>BuKyung Kim</name>
      <address>
        <city>Busan</city>
        <zip>49267</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MyungOne Ha</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 6, 2021</study_first_submitted>
  <study_first_submitted_qc>October 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2021</study_first_posted>
  <last_update_submitted>October 6, 2021</last_update_submitted>
  <last_update_submitted_qc>October 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Arteriosclerosis Obliterans</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarpogrelate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

